Role of 68Ga-FAPI-04 PET/CT in the Initial Staging of Esophageal Cancer
- Nuklearmedizin. 2023 Feb;62(1):38-44. doi: 10.1055/a-1984-8044.
- 1. Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- 2. Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- 3. Academician (Expert) Workstation of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- 4. Institute of Nuclear Medicine, Southwest Medical University, Luzhou, China.
- 5. Department of Nuclear Medicine, The Yibin No. 2 People's Hospital, Yibin, China.
- 6. Department of Thoracic Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Aim: To investigate the clinical value of 68Ga-FAPI-04 PET/CT for initial staging of esophageal Cancer.
Methods: A total of 44 newly diagnosed patients with esophageal Cancer were included in the analysis on the basis of postoperative pathology or clinical and radiologic follow-up.
Results: All primary lesions showed increased 68Ga-FAPI-04 uptake, with an SUVmax of 14.92 ± 6.91. A total of 561 lymph nodes were verified by surgery (507) or clinical and radiologic follow-up (54), of which 92 lymph nodes were diagnosed as showing metastases. Seventy-five lymph nodes with metastases showed positive findings on 68Ga-FAPI-04, with a diameter of about 1.06 ± 0.53 cm and SUVmax of 8.10±4.71. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for lymph node metastasis detection were 81.5%, 99.3%, 96.6%, 96.2%, and 96.5%, respectively.
Conclusion: 68Ga-FAPI-04 PET/CT showed good diagnostic performance in detecting lymph node metastases of esophageal Cancer.